Vitamin D3 for Life

Live Enlightened

Physiology

Why Vitamin D Autoimmune Findings Differ: Study Summary

Previous related pageWhy Vitamin D Autoimmune Findings Differ: Full Evidence ReviewNext related pageWhy Vitamin D Autoimmune Findings Differ: Full Evidence Review
Study at a glance

What was the question?

Why do vitamin D studies reach different conclusions about autoimmunity? The review asks whether they measured the same exposure, disease stage and outcome before trying to explain the difference.

Who or what was studied?

Two investigations followed children at increased risk of type 1 diabetes. Two used inherited genetic variants to study vitamin D status and disease susceptibility. Additional brain and mouse research helped explain the limits of tissue and immune measurements.

What did the studies find?

The childhood associations differed. One genetic analysis supported a role for lower vitamin D status in multiple sclerosis susceptibility. The type 1 diabetes genetic analysis did not establish a clear overall effect. These studies used different instruments, populations and outcomes; the contrast alone does not prove that their true effects differ.

What does this mean?

A genetic tendency over life is not the same as starting supplements now. Timing and tissue context can matter, but they do not automatically explain every disagreement. A result that is not statistically clear does not prove zero effect. These findings do not establish a personal blood target, genetic treatment test or supplement plan.

Read the full article below ↓

Different vitamin D studies do not necessarily estimate the same effect. Some follow measured blood status before early autoimmune markers. Others use inherited genetic variants to study lifelong tendencies and disease susceptibility. This review compares those approaches without assuming that every difference has one biological explanation. For the detailed analysis, read Why Vitamin D Autoimmune Findings Differ: Full Evidence Review.

The childhood observations did not agree consistently

TEDDY linked higher measured vitamin D status with lower odds of persistent islet autoantibodies in children at increased genetic risk of type 1 diabetes. DAISY did not find a clear measured-status association with autoimmunity or progression to diabetes. Their exposure scales, measurement windows and analysis groups differed. Neither was a randomized prevention trial. [1] [2]

TEDDY also found evidence that an association varied with a receptor variant. The strength of this interaction depended on the time window and adjustment for multiple tests. It does not establish a genetic test for choosing a supplement regimen. The childhood average included first antibody detection, so the entire exposure cannot be placed before biological initiation.

Vitamin D and Immune Tolerance concerns restraint of self-directed immunity. Detecting an antibody, showing functional suppression and diagnosing disease are different measurements of that wider process. Their timing cannot be treated as interchangeable.

Genetic analyses asked a different question

Mendelian randomization uses variants associated with an exposure to examine its possible effect on an outcome. It can reduce some problems of disease altering the measured exposure. It still depends on assumptions about the variants, including whether they influence disease through other routes. Vitamin D Genetics provides background on interpreting genetic evidence without individual determinism.

Mokry’s multiple-sclerosis study supported an association between genetically influenced lower vitamin D status and greater MS susceptibility. Its sensitivity analyses supported the interpretation but could not prove every genetic assumption. The published correction added an author and repaired a pathway figure; the corrected material was assessed. The result is not an adult supplementation trial. [10]

Manousaki’s type 1 diabetes analysis did not establish a clear overall effect. Its confidence interval allowed a range of effects, and a sensitivity analysis identified outlier-related pleiotropy. Removing outliers did not produce a significant association. A background-reference correction was assessed. Other panel and sample-total discrepancies are retained as limitations rather than used for unsupported numerical claims. [11]

Why a positive result and a null result are not a complete explanation

A clear result in one disease and a non-significant result in another do not themselves prove that the true effects differ. These analyses used different instruments and datasets. A lifelong genetic tendency is not equivalent to starting a supplement now, and a null average estimate cannot settle every possible timing or nonlinear question. Those remaining possibilities are hypotheses, not demonstrated benefits.

Additional evidence illustrates context without explaining the genetic contrast. Ramasamy measured regional expression in healthy brain, not hormone production in diseased lesions. Driver showed how receptor-deficient mice’s metabolic context could affect diabetes expression; unavailable supplementary figures limit detailed immune-function claims. Casteels tested functional cell transfer in a perturbed mouse model; a missing figure caption limits apoptosis detail. These remain three separate, bounded observations. [7] [4] [5]

Vitamin D and the Timing of Immune Activation and Restraint: Full Evidence Review explains why timing needs to be measured, not merely proposed after results differ. The selected evidence supports disease-specific interpretation: supportive MS genetic findings, uncertain childhood associations and no clear overall T1D genetic effect. It does not support a universal autoimmune prevention claim or genotype-guided self-treatment.

Scientific sources and access

Evidence assessed on 5 November 2026. This is an original synthesis of selected research, not a reproduction of the papers or a systematic review. Material source-access limits are identified in the analysis.

[1] Norris and colleagues. Plasma 25-Hydroxyvitamin D Concentration and Risk of Islet Autoimmunity. Diabetes. 2018 Jan;67(1):146 to 154. DOI: 10.2337/db17-0802. PMID: 29061729.

[2] Simpson and colleagues. No association of vitamin D intake or 25-hydroxyvitamin D levels in childhood with risk of islet autoimmunity and type 1 diabetes: the Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia. 2011 Nov;54(11):2779 to 2788. DOI: 10.1007/s00125-011-2278-2. PMID: 21858504.

[4] Driver and colleagues. Calcium insufficiency accelerates type 1 diabetes in vitamin D receptor-deficient nonobese diabetic (NOD) mice. Endocrinology. 2011 Dec;152(12):4620 to 4629. DOI: 10.1210/en.2011-1074. PMID: 21952242.

[5] Casteels and colleagues. 1,25-Dihydroxyvitamin D3 restores sensitivity to cyclophosphamide-induced apoptosis in non-obese diabetic (NOD) mice and protects against diabetes. Clinical and experimental immunology. 1998 May;112(2):181 to 187. DOI: 10.1046/j.1365-2249.1998.00568.x. PMID: 9649179.

[7] Ramasamy and colleagues. Genetic evidence for a pathogenic role for the vitamin D3 metabolizing enzyme CYP24A1 in multiple sclerosis. Multiple sclerosis and related disorders. 2014 Mar;3(2):211 to 219. DOI: 10.1016/j.msard.2013.08.009. PMID: 25568836.

[10] Mokry and colleagues. Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study. PLoS medicine. 2015 Aug;12(8):e1001866. DOI: 10.1371/journal.pmed.1001866. PMID: 26305103.

[11] Manousaki and colleagues. Vitamin D levels and risk of type 1 diabetes: A Mendelian randomization study. PLoS medicine. 2021 Feb;18(2):e1003536. DOI: 10.1371/journal.pmed.1003536. PMID: 33630834.

Mokry and colleagues. Correction: Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study. PLOS Medicine. 2016. DOI: 10.1371/journal.pmed.1001981. PMID: 26963823.

Manousaki and colleagues. Correction: Vitamin D levels and risk of type 1 diabetes: A Mendelian randomization study. PLOS Medicine. 2021. DOI: 10.1371/journal.pmed.1003624. PMID: 33914743.

Related reading

Original sources

Source

No association of vitamin D intake or 25-hydroxyvitamin D levels in childhood with risk of islet autoimmunity and type 1 diabetes: the Diabetes Autoimmunity Study in the Young (DAISY)

[2] Simpson and colleagues.

Publication details

[2] Simpson and colleagues. No association of vitamin D intake or 25-hydroxyvitamin D levels in childhood with risk of islet autoimmunity and type 1 diabetes: the Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia. 2011 Nov;54(11):2779 to 2788. DOI: 10.1007/s00125-011-2278-2. PMID: 21858504.

Read more →
Source

1,25-Dihydroxyvitamin D3 restores sensitivity to cyclophosphamide-induced apoptosis in non-obese diabetic (NOD) mice and protects against diabetes

Published in Clinical and experimental immunology. 1998 May;112(2):181 to 187. DOI: 10.1046/j.1365-2249 (1998).

Publication details

[5] Casteels and colleagues. 1,25-Dihydroxyvitamin D3 restores sensitivity to cyclophosphamide-induced apoptosis in non-obese diabetic (NOD) mice and protects against diabetes. Clinical and experimental immunology. 1998 May;112(2):181 to 187. DOI: 10.1046/j.1365-2249.1998.00568.x. PMID: 9649179.

Read more →
Source

Genetic evidence for a pathogenic role for the vitamin D3 metabolizing enzyme CYP24A1 in multiple sclerosis

Published in Multiple sclerosis and related disorders. 2014 Mar;3(2):211 to 219. DOI: 10.1016/j.msard (2013).

Publication details

[7] Ramasamy and colleagues. Genetic evidence for a pathogenic role for the vitamin D3 metabolizing enzyme CYP24A1 in multiple sclerosis. Multiple sclerosis and related disorders. 2014 Mar;3(2):211 to 219. DOI: 10.1016/j.msard.2013.08.009. PMID: 25568836.

Read more →